🇺🇸 FDA
Patent

US 11597924

Genome editing systems comprising repair-modulating enzyme molecules and methods of their use

granted A61KA61K31/7088A61K38/45

Quick answer

US patent 11597924 (Genome editing systems comprising repair-modulating enzyme molecules and methods of their use) held by Editas Medicine, Inc. expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Editas Medicine, Inc.
Grant date
Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/7088, A61K38/45, A61K38/465, A61K48/005